Verition Fund Management
SWTX

Verition Fund Management’s SpringWorks Therapeutics SWTX Stock Holding History

Verition Fund Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,400
Closed -$2.22M – 3855
2025
Q1 		$2.22M Buy
+50,400
New +$2.32M 0.01% 1495

Other funds holding SWTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Verition Fund Management's SWTX Position: Q3 2025 in Review

Verition Fund Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 313,408 shares — an estimated $14.7M sold.

Verition Fund Management first reported a position in SWTX in Q4 2023 and held it in 5 quarters. The position peaked at $14.7M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

  • Verition Fund Management reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 313,408 SpringWorks Therapeutics shares in Q3 2025, an estimated $14.7M.
  • Verition Fund Management first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 5 quarters.
  • Verition Fund Management's SpringWorks Therapeutics position peaked at $14.7M in Q2 2025.
  • 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.